BUY Piramal Pharma Limited — ICICI Securities
byICICI SecuritiesHorizon: NA (inferred 1 year)30 Apr 2026via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Yapan Bio to become Piramal subsidiary following acquisition
NewsGoogle News·20 Aug · yesterday
Piramal Pharma Limited has acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its shareholding from 33.33% to 74.00%. Yapan has now become a subs
NSE · Acquisition·18 Aug · 3d ago
Piramal Pharma Ltd has acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its shareholding from 33.33% to 74.00%. Yapan will now become a subsidi
BSE · Company Update·18 Aug · 3d ago
Piramal Pharma Ltd has provided an update regarding the exercise of a call option to acquire an additional equity stake in Yapan Bio Private Limited.
BSE · Company Update·10 Aug · 1w ago
2 advisors have active short-term BUY calls on this stock
Advisor consensus · adjacent horizon·6 Aug · 2w ago
Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore
NewsCnbc-Tv18·13 Aug · 1w ago
Buy, Sell Or Hold: Mahindra & Mahindra, UltraTech Cement, Piramal Pharma, Groww And Swiggy — Ask Profit
NewsNdtv-Profit·30 Jul · 3w ago
Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·29 Jul · 3w ago
Piramal Pharma temporarily suspends Ahmedabad plant operations due to heavy rainfall
NewsCnbc-Tv18·25 Jul · 4w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Piramal Pharma
- BUY — Nirav Chheda, Nirmal Bang Securities24 Sept 2026 · ~1 year · target ₹250 · Active
- BUY — Rakesh Bansal24 Sept 2026 · Same day · target ₹219 · SL hit
- BUY — Goldman Sachs24 Sept 2026 · ~1 year · target ₹250 · Active
- BUY — Sacchitanand Uttekar, Tradebulls Securities22 Sept 2026 · ~3 months · target ₹230 · SL hit
- BUY — Siddharth Rai Mangala21 Sept 2026 · ~2 weeks · target ₹230 · SL hit
More from ICICI Securities
- BUY The Indian Hotels Company22 Oct 2026 · ~1 year · target ₹969 · Active
- BUY Just Dial21 Oct 2026 · ~1 year · target ₹850 · Active
- BUY Union Bank of India20 Oct 2026 · ~1 year · target ₹230 · Active
- BUY Rossari Biotech20 Oct 2026 · ~1 year · target ₹520 · Active
- BUY Tatva Chintan Pharma Chem20 Oct 2026 · ~1 year · target ₹2,385 · Active

